Original article title
Adjuvant mFOLFOXIRI after curative-intent resection of oligometastatic colorectal cancer: phase II FANTASTIC trial.
Takeaway
In this nonrandomized phase II study, 74% completed eight cycles of intensive postoperative mFOLFOXIRI. Positive circulating tumor DNA identified higher recurrence risk; apparent treatment benefits require randomized confirmation because comparison groups were selected differently.
Keep in mind
Small nonrandomized phase II trial.
pubmed.ncbi.nlm.nih.gov · Full-text access depends on the publisher.
The takeaway was checked against source text. The original title is preserved above.
This is a reading aid. Follow the source for methods, limitations, corrections, and clinical context.